ACSL4 and breast cancer: Additionally, studies have indicated that the combined levels of ACSL4/GPX4 in BC patients without a family history can serve as a novel predictor and prognostic biomarker for pathological complete remission in patients receiving neoadjuvant chemotherapy (116).